U.S. Biotech Breakthroughs

Alnylam Pharmaceuticals

Market Cap: US$60.1b

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.

Caris Life Sciences

Market Cap: US$8.6b

An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.

Mereo BioPharma Group

Market Cap: US$286.4m

A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.

Legend Biotech

Market Cap: US$6.1b

Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.

ARS Pharmaceuticals

Market Cap: US$982.3m

A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.

Vanda Pharmaceuticals

Market Cap: US$281.3m

A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.

OS Therapies

Market Cap: US$70.9m

A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.

RenovoRx

Market Cap: US$44.0m

A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.

Capricor Therapeutics

Market Cap: US$283.0m

A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

Tenaya Therapeutics

Market Cap: US$254.2m

A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.

Aldeyra Therapeutics

Market Cap: US$300.8m

A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.

Soleno Therapeutics

Market Cap: US$3.4b

A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Madrigal Pharmaceuticals

Market Cap: US$9.5b

A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.

Achieve Life Sciences

Market Cap: US$157.4m

A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.

AC Immune

Market Cap: US$249.3m

A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.

Syndax Pharmaceuticals

Market Cap: US$1.3b

A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.

Arcutis Biotherapeutics

Market Cap: US$2.1b

A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.

Altimmune

Market Cap: US$334.5m

A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.

Invivyd

Market Cap: US$226.1m

A biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.

XOMA Royalty

Market Cap: US$454.5m

Operates as a biotech royalty aggregator in the United States and the Asia Pacific.

Insmed

Market Cap: US$29.8b

Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

Ocugen

Market Cap: US$512.2m

A biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health.

Rhythm Pharmaceuticals

Market Cap: US$6.6b

A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.

Ardelyx

Market Cap: US$1.5b

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.

Iovance Biotherapeutics

Market Cap: US$749.0m

A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.

Unicycive Therapeutics

Market Cap: US$68.0m

A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.

Anavex Life Sciences

Market Cap: US$724.9m

Operates as a biopharmaceutical company.

BioRestorative Therapies

Market Cap: US$11.6m

Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.

BeOne Medicines

Market Cap: US$36.3b

An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

Marker Therapeutics

Market Cap: US$11.8m

A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.

Evaxion

Market Cap: US$20.8m

A clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.

Creative Medical Technology Holdings

Market Cap: US$8.0m

A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.

Day One Biopharmaceuticals

Market Cap: US$703.7m

A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.

Sierra Oncology

Market Cap: US$1.3b

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs.

KalVista Pharmaceuticals

Market Cap: US$657.8m

A biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.

Arcturus Therapeutics Holdings

Market Cap: US$550.2m

Engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases.